Hyperparathyroidism in chronic kidney disease patients: An update on current pharmacotherapy

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 7, 2013, Pages 863-871

  Fukagawa, Masafumi ^a   Komaba, Hirotaka ^a   Kakuta, Takatoshi ^a  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Calcimimetics; Hyperparathyroidism; Parathyroid hormone; Phosphate binder; Phosphorus; Vitamin D receptor activator

Indexed keywords

ALUMINUM; BIXALOMER; CALCIMIMETIC AGENT; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CINACALCET; COLESTILAN; FARGAMATE; FERRIC CITRATE; FIBROBLAST GROWTH FACTOR 23; FIBROBLAST GROWTH FACTOR 23 ANTIBODY; IRON; IRON MAGNESIUM HYDROCARBONATE; IRON OXIDE HYDROXIDE STARCH SUCROSE CARBONATE COMPLEX; JTT 751; KRX 751; LANTHANUM CARBONATE; MAGNESIUM CARBONATE; NEUTRALIZING ANTIBODY; OSVAREN; PA 21; PARATHYROID HORMONE; PHENOBARBITAL; PHOSPHATE BINDING AGENT; PHOSPHORUS; POLYNUCLEAR IRON OXYHYDROXIDE; SBR 759; SEVELAMER; SEVELAMER CARBONATE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITAMIN D RECEPTOR; WARFARIN; ZERENEX;

ANEMIA; ATHEROSCLEROSIS; BLOOD VESSEL CALCIFICATION; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONSTIPATION; DIET THERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; HYPERCHOLESTEROLEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; IRON BLOOD LEVEL; NEPHRON; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HORMONE RELEASE; PATHOGENESIS; PHASE 3 CLINICAL TRIAL (TOPIC); PHOSPHATE BLOOD LEVEL; PHOSPHATURIA; PROTEIN RESTRICTION; RENAL REPLACEMENT THERAPY; REVIEW; SECONDARY HYPERPARATHYROIDISM; UNSPECIFIED SIDE EFFECT;

BONE AND BONES; CALCIMIMETIC AGENTS; CHELATING AGENTS; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; HYPERPHOSPHATEMIA; MEDICATION ADHERENCE; NAPHTHALENES; RECEPTORS, CALCITRIOL; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D;

EID: 84876051053     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.783017     Document Type: Review

References (101)

1. Fukagawa M, Hamada Y, Nakanishi S, et al. The kidney and bone metabolism: a nephrologist's point of view. J Bone Miner Metab 2006;24:434-8
2. Bergstrand H. Parathyreoideastudien. II. Uber Tumoren und hyperplastische Zustande der Nebenschilddrusen. Acta Med Scand 1921;54:539-600
3. Hubbard RS, Wentworth JA. A case of metastatic calcification associated with chronic nephritis and hyperplasia of the parathyroids. Proc Soc Expert Biol Med 1921;18:307-8
4. Albright F, Drake TG, Sulkowitch HW. Renal osteitis fibrosa cyctica: report of case with discussion of metabolic aspects. Bull John Hopkins Med J 1937;60:377-85
5. Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcome (KDIGO). Kidney Int 2006;69:1945-53
6. Komaba H, Kakuta T, Fukagawa M. Diseases of the parathyroid gland in chronic kidney disease. Clin Exp Nephrol 2011;15:797-809
7. National Kidney Foundation. K/DOQI clinical guidelines. Am J Kidney Dis 2003;42(Suppl 3):S1-S201
8. Barreto FC, Barreto DV, Moyses RM, et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008;73:771-7
9. Iwasaki Y, Yamato H, Nii-Kono T, et al. Insufficiency of PTH action on bone in uremia. Kidney Int 2006;70(Suppl 102):S34-6
10. Kidney disease: improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guidelone for the diagnosis, evaluation, prevention and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009;76(Suppl 113):S1-S130
11. Guideline working group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Aphr Dial 2008;12:514-25
12. Fukagawa M, Yokoyama K, Koiwa F, et al. Clinical practice guideline for the management of Chronic Kidney disease-mineral and bone disorder (CKDMBD). Ther Aphr Dial; In press
13. Taniguchi M, Fukagawa M, Fujii N, et al. Impact of mineral metabolism on mortality in hemodialysis patients: serum phosphate level should be controlled firstly and consistently. Ther Aphr Dial; In press
14. Slatopolsky E, Gradowska L, Kashemsant C, et al. The control of phosphate excretion in uremia. J Clin Invest 1966;45:672-7
15. Slatopolsky E, Caglar S, Pennell JP, et al. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest 1971;50:492-9
16. Portale AA, Halloran BP, Murphy MM, et al. Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. J Clin Invest 1986;77:7-12
17. Yi H, Fukagawa M, Yamato H, et al. Preventio of enhanced parathyroid hormone synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. Nephron 1995;70:242-8
18. Almaden Y, Hernandez A, Torregrosa V, et al. High phosphate level directly stimulate sparathyroid hormone secretion and synthesis by human parathyroid tissue in vitro. J Am Soc Nephrol 1998;9:1845-52
19. Sera-Brown A, Silver J, Brewer G, et al. Identification of AUF1 as a parathyroid hormone mRNA 3′-untranslated regionbinding protein that determines parathyroid hormone mRNA stability. J Biol Chem 2000;275:7424-9
20. Shimada T, Mizutani S, Muto T, et al. Cloning and characterization as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001;98:6500-5
21. ADHR Consortium. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000;26:345-8
22. Komaba H, Fukagawa M. FGF23-parathyroid interaction. Kidney Int 77:292-8.2010
23. Perwad F, Zhang MY, Tenenhouse HS, et al. Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1alpha-hydroxylase expression in vitro. Am J Physiol Renal Physiol 2007;293:F1577-83
24. Isakova T, Wahl P, Vargas GS, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011;79:1370-80
25. Nakano C, Matsui I, Tomida S, et al. Combination use of vitamin D status and FGF23 for risk strafication of renal outcome. Clin J Am Soc Nephrol 2012;7:810-19
26. Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010;5(2):286-91
27. Slatopolsky E, Caglar S, Gradowska L, et al. On the prevention of secondary hyperparathyroidism in experimental chronic renal disease using "proportional reduction" of dietary phosphorus intake. Kidney Int 1972;2:147-51
28. Yamazaki Y, Tamada T, Kasai N, et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 2008;23:1509-18
29. Shalhoub V, Shatzen EM, Ward SC, et al. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest 2012;122:2543-453
30. Ketteler M, Biggar PH, Liangos O. FGF23 antagonism: the thin line between adaptation and maladaptation in chronic kidney disease. Nephrol Dial Transplant 2012; Epub ahead of print
31. Block GA, Wheeler D, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012;23:1407-15
32. Kalantar-Zadeh K, Gutekunst L, Mehorotra R, et al. Understanding sources of dietary phosphorus in the treatment of patients with chronic kidney disease. Clin J Am Soc Nephrol 2010;5:519-30
33. Fukagawa M, Komaba H, Miyamoto K-I. Editorial: source matters: from phosphorus load to bioavailability. Clin J Am Soc Nephrol 2011;6:239-40
34. Ritz E, Hahn K, Ketteler M, et al. Phosphate additives in food: a health risk. Dtsch Arztebl Int 2012;109:49-55
35. Sullivan C, Sayre SS, Leon JB, et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease. JAMA 2009;301:629-35
36. Bammens B, Evenepoel P, Verbenke K, et al. Removal of middle molecules and protein bound solutes by peritoneal dialysis and relation with uremic symptoms. Kidney Int 2003;64:2238-43
37. Ayus JC, Mizani MR, Achinger SG, et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective controlled study. J Am Soc Nephrol 2005;16:2778-88
38. Pierratos A, Ouwendyk M, Francoeur R, et al. Nocturnal hemodialysis: three-year experience. J Am Soc Nephrol 1998;9:859-68
39. Slatopolsky E, Weerts C, Loppez-Hilker S, et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986;315:157-61
40. Delmez JA, Tindira CA, Windus DW, et al. Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 1992;3:96-102
41. Jamal SA, Fitchett D, Lok CE, et al. The effects of calcium-based versus non-calcium-based phosphate binders on mortality among patients with chronic kidney disease: a meta-analysis. Nephrol Dial Transplant 2009;24:3168-74
42. Chertow GM, Burke SK, Lazanus JM, et al. Poly[allylamine hydrochloride] (Rena Gel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997;29:66-71
43. Delmez J, Block G, Robertson J, et al. A randomized double-blind crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007;68:386-91
44. Chertow GM, Burke SK, Raggi P; Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52
45. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005;68:1815-24
46. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007;71:438-41
47. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007;72:1130-7
48. Quinbi W, Moustafa M, Muenz LR, et al. A 1 year randomized trial of calcium acetate versus sevalamer on progression of coronary artery calcification in hemodialysis patients with comparable lipid control: the Calciu Acetate Renage; Evaluation-2 (CARE-2) study. Am J Kidney Dis 2008;51:952-65
49. Chertow GW, Raggi P, McCarthy JT, et al. The effects of sevelamer and calcium acetate on proproxies of atherosclerotic and arteriosclerotic vascular disease in hemodialysis patients. Am J Nephrol 2003;23:307-14
50. Navarro-Gonzalez JF, Mora-Fernandez C, Muro de Fuentes M, et al. Effect of phosphate binders on serum inflammatory profile, soluble CD14, and endotoxin levels in hemodialysis patients. Clin J Am Soc Nephrol 2011;6:2272-89
51. Brandenburg VW, Schlieber G, Heussen N, et al. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant 2010;25:2672-9
52. Kakuta T, Tanaka R, Hyodo T, et al. Sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis 2011;57:422-31
53. Chiang SS, Chen JB, Yang QC. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease. Clin Nephrol 2005;63:461-70
54. Sprague ST, Abboud H, Qiu P, et al. Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial. Clin J Am Soc Nephrol 2009;4:178-85
55. Hutchison AJ, Barnett ME, Krause R, et al. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 2008;110:c15-23
56. Nikolov IG, Joki N, Nguyen-Khoa T, et al. Lanthanum carbonate, like sevelamer-HCL, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice. Nephrol Dial Transplant 2012;27:505-13
57. Toussaint ND, Lan KK, Polkinghorne KR, et al. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in hemodialysis: a pilot randomized controlled trial. Nephrology 2011;16:290-8
58. Fraile P, Cacharro LM, Garcia-Cosmes P, et al. Encephalopathy caused by lanthanum carbonate. NDT Plus 2011;4:192-4
59. Kurihara S, Tsuruta Y, Akizawa T. Effect of MCI-106 (colestilan) as a phosphate binder on hyperphosphatemia in haemodialysis patients: a double-blind, placebo-controlled, short-term trial. Nephrol Dial Transplant 2005;20:424-30
60. Locattelli F, Dimkovic N, Pontoriero G, et al. Effect of MCI-196 on serum phosphate and cholesterol levels. Nephrol Dial Transplant 2010;25:574-81
61. Akizawa T, Ogigasa H, Kameoka C, et al. A phase III, sevelamer HCl-controlled study of bixalomer in chronic kidney disease patients on hemodialysis with hyperphosphatemia (abstract) FR-PO1669. ASN Kidney Week; 2011
62. Akizawa T, Kameoka C; Bixalomer Study Group. Long-term treatment of bixalomer in chronic kidney disease patients on hemodialysis with hyperphosphatemia (abstract). FR-PO1667. ASN Kidney Week; 2011
63. Yokoyama K, Hirakata H, Akiba T, et al. Effect of oral JTT-751. Ferric Citrate) on hyperphosphatemia in hemodialysis patients: results of a randomized, double-blind, placebo-controlled trial. Am J Nephrol 2012;36:478-87
64. Sinsaku M, Sika M, Koury M, et al. The safety and tolerability of ferric citrate as a phosphate binder in dialysis patients. Nephron Clin Pract 2012;121:c25-9
65. Geisser P, Philipp E. PA21: a novel phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease. Clin Nephrol 2010;74:4-11
66. Wuthrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 2013;8(2):280-9
67. Block GA, Brillhart SL, Persky MS, et al. Efficacy and safety of SBR759, a new iron-based phosphate binder. Kidney Int 2010;77:897-903
68. Chen JB, Chiang SS, Chen HC, et al. Efficacy and safety of SBR759, a novel iron (III)-based phosphate binder, in patients undergoing hemodialysis: a 12 week, randomized, open-label, dose-titration study versus sevelamer hydrochloride. Nephrology 2011;16:743-50
69. McIntyre CW, Pai P, Warwick G, et al. Iron-magnesium hydroxycarbonate (Fermagate): a novel non-calcium containing phosphate binder for the treatment of hyperphosphatemia in chronic dialysis patients. Clin J Am Soc Nephrol 2009;4:401-9
70. De Francisco ALM, Leidig M, Covic A, et al. Evaluation of calcium acetate/magnecium carbonate as a phosphate binder compared with sevelamer hydrochloride in hemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010;25:3707-17
71. Shimoda K, Akiba T, Matsushima T, et al. Niceritrol decreases serum phosphate levels in chronic dialysis patients. Nihon Jinzo Gakkai Shi (Japanese) 1998;40:1-7
72. Takahashi Y, Tanaka A, Nakamura T, et al. Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004;65:1099-104
73. Cheng SC, Young DO, Huang Y, et al. A randomized, double blind, placebo-controlled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1131-8
74. Kuboyama N, Watanabe Y, Yamaguchi M, et al. Effect of niceritrol on faecal and urinary phosphate excretion in normal rats. Nephrol Dial Transplant 1999;14:610-14
75. Katai K, Tanaka H, Tatsumi S, et al. Nicotinamide inhibits sodium-dependent phosphate cotransport activity in rat small intestine. Nephrol Dial Transplant 1999;14:1195-201
76. Hutchison AJ, Smith CP, Brechley PE. Pharmacology, efficacy and safety of oral phosphate binders. Nat Rev Nephrol 2011;7:578-89
77. Adenas MD, Malek T, Gil MT, et al. Challenge of phosphorus control in hemodialysis patients: a adherence? J Nephrol 2010;23:525-34
78. Goto S, Komaba H, Moriwaki K, et al. Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. Clin J Am Soc Nephrol 2011;6:1375-84
79. Tanaka H, Hamano T, Fujii N, et al. The impact of diabetes mellitus on vitamin D metabolism in predialysis patients. Bone 2009;45:949-55
80. Fukagawa M, Komaba H, Hamano T. Vitamin D supplement in renal disease: is calcitriol all that needed? Scand J Clin Lab Invest 2012;72(Suppl 243):120-3
81. de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a rondamized controlled trial. Lancet 2010;376:1543-51
82. Cheng J, Zhang W, Zhang X, et al. Efficacy and safety of paricalcitol therapy for chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2012;7:391-400
83. Thadhani R, Appelbaum E, Pritchett Y, et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012;307:674-84
84. Tamez H, Zoccali C, Packham D, et al. Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J 2012;164:902-9
85. Fukagawa M, Nakanishi S, Kazama JJ. Basic and clinical aspects of parathyroid hyperplasia in chronic kidney disease. Kidney Int 2006;70(Suppl 102):S3-7
86. Sprague SM, Llach F, Amdahl M, et al. Paricaicitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003;63:1483-90
87. Akizawa T, Suzuki M, Akiba T, et al. Clinical effects of maxacalcitol on secondary hyperparathyroidism of uremic patients. Am J Kidney Dis 2001;38(Suppl 1):S147-51
88. Hayashi M, Tsuchiya Y, Itaya Y, et al. Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicenter trial. Nephrol Dial Transplant 2004;19:2063-73
89. Block GA, Martin KJ, de Francisco AL, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25
90. Fukagawa M, Yumita S, Akizawa T, et al. Cinacalcet (KRN 1493) effectively decreases serum intact PTH level with favorable control of serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant 2008;23:328-35
91. Komaba H, Nakanishi S, Fujimori A, et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland hyperplasia regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010;5:2305-14
92. Cunningham J, Danese M, Olseon K, et al. Effects of calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005;68:1793-800
93. Fukagawa M, Fukuma S, Onishi Y, et al. Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study. Clin J Am Soc Nephrol 2012;7:1473-80
94. Komaba H, Moriwaki K, Goto S, et al. Cost effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism. Am J Kidney Dis 2012;60:262-71
95. Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011;26:1327-39
96. EVOLVE Trial Invsetigators. Chertow GM, Block GA, Correa-Rotter R, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012;367:2482-94
97. Baruch A, Maclean D, Yin K, et al. KAI-4169, a novel calcimimetics for the treatment for secondary hyperparathyroidism. Endocr Rev 2011;32(03-Meeting Abstracts):P2-98
98. Shiizaki K, Hatamura I, Fukagawa M, et al. Development of a technique for introduction of an expressed cDNA into parathyroid cells by direct injection. Endocrinology 2010;151:4031-8
99. Kanai G, Kakuta T, Sawada K, et al. Suppression of parathyroid hormone production in vitro and in vivo by RNA interference. Kidney Int 2009;75:490-8
100. Kakuta T, Fukagawa M, Fujisaki T, et al. Prognosis of parathyroid function after successful percutaneous ethanol injection therapy (PEIT) guided by color Doppler flow mapping in chronic dialysis patients. Am J Kidney Dis 1999;33:1091-9
101. Kitaoka M, Fukagawa M, Fukuda N, et al. Direct injections of calcitriol into parathyroid hyperplasia in chronic dialysis patients with severe parathyroid hyperfunction. Nephrology 1995;1:563-8